Therapeutic targets for prevention and regression of progressive fibrosing renal diseases

Current Opinion in Investigational Drugs

Volumn 6, Issue 3, 2005, Pages 255-261

  Eitner, Frank ^a   Floege, Jürgen ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Bone morphogenic protein; Chemokine; Hepatocyte growth factor; Platelet derived growth factor; Renin angiotensin aldosterone system; Transforming growth factor

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; 2 BROMOETHYLAMINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBRINOLYTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BONE MORPHOGENETIC PROTEIN; BRADYKININ ANTAGONIST; CHEMOKINE; CHEMOKINE RECEPTOR ANTAGONIST; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GEFITINIB; IMATINIB; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 1 ANTAGONIST; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT OSTEOGENIC PROTEIN 1; RECOMBINANT RELAXIN; RECOMBINANT SCATTER FACTOR; RELAXIN; SCATTER FACTOR; SMAD3 PROTEIN; SMAD7 PROTEIN; SPIRONOLACTONE; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CHRONIC KIDNEY DISEASE; CONTINUOUS INFUSION; DISEASE COURSE; DRUG ANTAGONISM; DRUG STRUCTURE; DRUG TARGETING; GENE THERAPY; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FIBROSIS; LEUKOCYTE ACTIVATION; NEPHRITIS; NEPHROTOXICITY; NONHUMAN; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SYSTEMATIC REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BONE MORPHOGENETIC PROTEINS; CHEMOTAXIS, LEUKOCYTE; FIBROSIS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HEPATOCYTE GROWTH FACTOR; HUMANS; KIDNEY DISEASES; KIDNEY TUBULES; LYMPHOCYTE ACTIVATION; PLATELET-DERIVED GROWTH FACTOR; RELAXIN; RENIN-ANGIOTENSIN SYSTEM; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTORS;

EID: 15844395661     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Iwano M, Neilson EG: Mechanisms of tubulointerstitial fibrosis. Curr Opin Nephrol Hypertens (2004) 13(3):279-284.
2. Kalluri R, Neilson EG: Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest (2003) 112 12):1776-1784.
3. Liu Y: Epithelial to mesenchymal transition in renal fibrogenesis: Pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol (2004) 15(1):1-12.
4. Branton MH, Kopp JB: TGF-β and fibrosis. Microbes Infect (1999) 1(15):1349-1365.
5. Tamaki K, Okuda S: Role of TGF-β in the progression of renal fibrosis. Contrib Nephrol (2003) 139:44-65.
6. Fukasawa H, Yamamoto T, Suzuki H, Togawa A, Ohashi N, Fujigaki Y, Uchida C, Aoki M, Hosono M, Kitagawa M, Hishida A et al: Treatment with anti-TGF-β antibody ameliorates chronic progressive nephritis by inhibiting Smad/TGF-β signaling. Kidney Int (2004) 65 1):63-74.
7. Bottinger EP, Letterio JJ, Roberts AB: Biology of TGF-β in knockout and transgenic mouse models. Kidney Int (1997) 51 5):1355-1360.
8. Ma L, Fogo AB: Role of angiotensin II in glomerular injury. Semin Nephrol (2001) 21(6):544-553.
9. Daniel C, Takabatake Y, Mizui M, Isaka Y, Kawashi H, Rupprecht H, Imai E, Hugo C: Antisense oligonucleotides against thrombospondin-1 inhibit activation of TGF-β in fibrotic renal disease in the rat in vivo. Am J Pathol (2003) 163(3):1185-1192.
10. Li JH, Zhu HJ, Huang XR, Lai KN, Johnson RJ, Lan HY: Smad7 inhibits fibrotic effect of TGF-β on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol (2002) 13(6):1464-1472.
11. Lan HY, Mu W, Tomita N, Huang XR, Li JH, Zhu HJ, Morishita R, Johnson RJ: Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol (2003) 14(6):1535-1548.
12. Fukasawa H, Yamamoto T, Togawa A, Ohashi N, Fujigaki Y, Oda T, Uchida C, Kitagawa K, Hattori T, Suzuki S, Kitagawa M, Hishida A: Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci USA (2004) 101(23):8687-8692.
13. Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A: Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest (2003) 112(10):1486-1494.
14. Klahr S, Morrissey J: Obstructive nephropathy and renal fibrosis: The role of bone morphogenic protein-7 and hepatocyte growth factor. Kidney Int Suppl (2003) (87):S105-S112.
15. Li T, Surendran K, Zawaideh MA, Mathew S, Hruska KA: Bone morphogenetic protein 7: A novel treatment for chronic renal and bone disease. Curr Opin Nephrol Hypertens (2004) 13(4):417-422.
16. Zelsberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R: BMP-7 counteracts TGF-β1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med (2003) 9(7):964-968.
17. Liu Y: Hepatocyte growth factor in kidney fibrosis: Therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol (2004) 287(1):F7-F16.
18. Gong R, Rifai A, Tolbert EM, Centracchio JN, Dworkin LD: Hepatocyte growth factor modulates matrix metalloproteinases and plasminogen activator/plasmin proteolytic pathways in progressive renal interstitial fibrosis. J Am Soc Nephrol (2003) 14(12):3047-3060.
19. Dai C, Yang J, Bastacky S, Xia J, Li Y, Liu Y: Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice. J Am Soc Nephrol (2004) 15 10):2637-2647.
20. Dworkin LD, Gong R, Tolbert E, Centracchio J, Yano N, Zanabli AR, Esparza A, Rifai A: Hepatocyte growth factor ameliorates progression of interstitial fibrosis in rats with established renal injury. Kidney Int (2004) 65(2):409-419.
21. Abdel Wahab N, Mason RM: Connective tissue growth factor and renal diseases: Some answers, more questions. Curr Opin Nephrol Hypertens (2004) 13(1):53-58.
22. Yokoi H, Mukoyama M, Nagae T, Mori K, Suganami T, Sawai K, Yoshioka T, Koshikawa M, Nishida T, Takigawa M, Sugawara A, Nakao K: Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol (2004) 15 6):1430-1440.
23. Bonner JC: Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev (2004) 15(4):255-273.
24. Ostendorf T, Kunter U, Grone HJ, Bahlmann F, Kawachi H, Shimizu F, Koch KM, Janjic N, Floege J: Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol (2001) 12(5):909-918.
25. Levitzki A: PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases. Cytokine Growth Factor Rev (2004) 15 4):229-235.
26. Eitner F, Ostendorf T, Van Roeyen C, Kitahara M, Li X, Aase K, Grone HJ, Eriksson U, Floege J: Expression of a novel PDGF isoform, PDGF-C, in normal and diseased rat kidney. J Am Soc Nephrol (2002) 13 5):910-917.
27. Eitner F, Ostendorf T, Kretzler M, Cohen CD, Eriksson U, Grone HJ, Floege J: PDGF-C expression in the developing and normal adult human kidney and in glomerular diseases. J Am Soc Nephrol (2003) 14(5):1145-1153.
28. Eitner F, Bucher E, Kunter U, Song R, Van Roeyen C, Eriksson U, Ostman A, Floege J, Ostendorf T: Neutralizing PDGF-CC prevents tubulointerstitial fibrosis in mice following unilateral ureteral obstruction. J Am Soc Nephrol (2004) 15:704A.
29. Taneda S, Hudkins KL, Topouzis S, Gilbertson DG, Ophascharoensuk V, Truong L, Johnson RJ, Alpers CE: Obstructive uropathy in mice and humans: Potential role for PDGF-D in the progression of tubulointerstitial injury. J Am Soc Nephrol (2003) 14 10):2544-2555.
30. Betsholtz C: Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev (2004) 15(4):215-228.
31. Liao X, Escobedo JA, Williams LT: Viability of transgenic mice expressing a platelet derived growth factor (PDGF) antagonist in plasma. J Investig Med (1996) 44(4):139-143.
32. Gilbert RE, Kelly DJ, McKay T, Chadban S, Hill PA, Cooper ME, Atkins RC, Nikolic-Paterson DJ: PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int (2001) 69(4):1324-1332.
33. Francois H, Placier S, Flamant M, Tharaux PL, Chansel D, Dussaule JC, Chatziantoniou C: Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J (2004) 18(7):926-928.
34. Wada T, Furuichi K, Sakai N, Iwata Y, Kitagawa K, Ishida Y, Kondo T, Hashimoto H, Ishiwata Y, Mukaida N, Tomosugi N et al: Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J Am Soc Nephrol (2004) 15(4):940-948.
35. Eis V, Luckow B, Vielhauer V, Siveke JT, Linde Y, Segerer S, De Lema GP, Cohen CD, Kretzler M, Mack M, Horuk R et al: Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction. J Am Soc Nephrol (2004) 16(2):337-347.
36. Anders HJ, Belemezova E, Eis V, Segerer S, Vielhauer V, Perez de Lema G, Kretzler M, Cohen CD, Frink M, Horuk R, Hudkins KL et al: Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice. J Am Soc Nephrol (2004) 15(6):1504-1513.
37. Mezzano SA, Ruiz-Ortega M, Egido J: Angiotensin II and renal fibrosis. Hypertension (2001) 38(3 Pt 2):635-638.
38. Remuzzi G, Ruggenenti P, Perico N: Chronic renal diseases: Renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med (2002) 136(8):604-615.
39. Adamczak M, Gross ML, Krtil J, Koch A, Tyralla K, Amann K, Ritz E: Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol (2003) 14 11):2833-2842.
40. Adamczak M, Gross ML, Amann K, Ritz E: Reversal of glomerular lesions involves coordinated restructuring of glomerular microvasculature. J Am Soc Nephrol (2004) 15(12):3063-3072.
41. Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, Chatziantoniou C: Regression of renal vascular and glomerular fibrosis: Role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol (2003) 14(5):1132-1144.
42. Schanstra JP, Neau E, Drogoz P, Arevalo Gomez MA, Lopez Novoa JM, Calise D, Pecher C, Bader M, Girolami JP, Bascands JL: In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest (2002) 110(3):371-379.
43. Okada H, Watanabe Y, Kikuta T, Kobayashi T, Kanno Y, Sugaya T, Suzuki H: Bradykinin decreases plasminogen activator inhibitor-1 expression and facilitates matrix degradation in the renal tubulointerstitium under angiotensin-converting enzyme blockade. J Am Soc Nephrol (2004) 15(9):2404-2413.
44. Hostetter TH, Ibrahim HN: Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol (2003) 14(9):2395-2401.
45. Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E, Ishibashi S: Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int (2004) 66 4):1493-1502.
46. Miyazaki M, Nishino T, Abe K, Furusu A, Koji T, Kohno S: Regulation of renal extracellular matrix metabolism. Contrib Nephrol (2003) 139:141-155.
47. Yang J, Shultz RW, Mars WM, Wegner RE, Li Y, Dai C, Nejak K, Liu Y: Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest (2002) 110(10):1525-1538.
48. Eddy AA: Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol (2002) 283(2):F209-F220.
49. Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA: A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest (2003) 112(3):379-388.
50. Garber SL, Mirochnik Y, Brecklin CS, Unemori EN, Singh AK, Slobodskoy L, Grove BH, Arruda JA, Dunea G: Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int (2001) 59(3):876-882.
51. McDonald GA, Sarkar P, Rennke H, Unemori E, Kalluri R, Sukhatme VP: Relaxin increases ubiquitin-dependent degradation of fibronectin in vitro and ameliorates renal fibrosis in vivo. Am J Physiol Renal Physiol (2003) 285(1):59-67.
52. Samuel CS, Zhao C, Bond CP, Hewitson TD, Amento EP, Summers RJ: Relaxin-1-deficient mice develop an age-related progression of renal fibrosis. Kidney Int (2004) 65(6):2054-2064.
53. Yang J, Dai C, Liu Y: Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. J Am Soc Nephrol (2002) 13 10):2464-2477.
54. Yu L, Border WA, Anderson I, McCourt M, Huang Y, Noble NA: Combining TGF-β inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int (2004) 66(5):1774-1784.